Literature DB >> 24047721

Sequential morphological changes in follow-up CT of pulmonary mucormycosis.

Ji Yung Choo1, Chang Min Park, Hyun-Ju Lee, Chang Hyun Lee, Jin Mo Goo, Jung-Gi Im.   

Abstract

PURPOSE: We aimed to describe the computed tomography (CT) features of pulmonary mucormycosis including sequential changes between follow-ups.
MATERIALS AND METHODS: Between June 2001 and May 2011, five patients (three males and two females; median age, 43 years; age range, 13-73 years) who had been pathologically diagnosed with pulmonary mucormycosis constituted our study population. Their clinical and CT features including sequential changes over follow-ups were evaluated retrospectively.
RESULTS: All patients were immunocompromised due to either hematologic diseases (n=3), diabetes mellitus (n=1), or steroid administration for autoimmune hepatitis (n=1). All patients had symptoms such as fever (n=5), tachycardia (n=1), or pleuritic chest pain (n=1) on admission. Regarding the clinical outcome after treatment, one patient died, and the remaining four recovered from the disease. In terms of initial CT features, the morphologies of pulmonary mucormycosis included a single mass (n=3), consolidation (n=1), or multiple masses (n=1). There were seven pulmonary lesions in total, 3-7 cm in size, which showed a CT halo sign (n=3), reversed-halo sign (n=2), or air-fluid levels (n=2). On follow-up CTs, the lesions of all patients contained necrosis. All three patients with a mass or masses with a CT halo sign on initial CT had a decreased surrounding halo followed by central necrosis, and the lesions gradually decreased in size on recovery.
CONCLUSION: Pulmonary mucormycosis usually manifests as a mass or masses with a halo or reversed-halo sign on the initial CT scan followed by a decreased extent of surrounding ground-glass opacities with the development of internal necrosis during follow-up.

Entities:  

Mesh:

Year:  2014        PMID: 24047721      PMCID: PMC4463253          DOI: 10.5152/dir.2013.13183

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  14 in total

1.  Residents' corner. Answer to case of the month #87: Pulmonary mucormycosis with angioinvasion of the left subclavian artery.

Authors:  Nancy Kim; James Barrie; Gregory Raymond
Journal:  Can Assoc Radiol J       Date:  2002-12       Impact factor: 2.248

2.  Disseminated mucormycosis in haematological patients: CT and MRI findings with pathological correlation.

Authors:  M Horger; H Hebart; H Schimmel; M Vogel; H Brodoefel; K Oechsle; U Hahn; M Mittelbronn; W Bethge; C D Claussen
Journal:  Br J Radiol       Date:  2006-09       Impact factor: 3.039

3.  Fleischner Society: glossary of terms for thoracic imaging.

Authors:  David M Hansell; Alexander A Bankier; Heber MacMahon; Theresa C McLoud; Nestor L Müller; Jacques Remy
Journal:  Radiology       Date:  2008-01-14       Impact factor: 11.105

4.  Pulmonary mucormycosis: radiologic findings in 32 cases.

Authors:  H P McAdams; M Rosado de Christenson; D C Strollo; E F Patz
Journal:  AJR Am J Roentgenol       Date:  1997-06       Impact factor: 3.959

5.  Reversed halo sign in pulmonary paracoccidioidomycosis.

Authors:  Emerson L Gasparetto; Dante L Escuissato; Taísa Davaus; Elza Maria F P de Cerqueira; Arthur Soares Souza; Edson Marchiori; Nestor L Müller
Journal:  AJR Am J Roentgenol       Date:  2005-06       Impact factor: 3.959

Review 6.  Spectrum of pulmonary aspergillosis: histologic, clinical, and radiologic findings.

Authors:  T Franquet; N L Müller; A Giménez; P Guembe; J de La Torre; S Bagué
Journal:  Radiographics       Date:  2001 Jul-Aug       Impact factor: 5.333

Review 7.  Novel perspectives on mucormycosis: pathophysiology, presentation, and management.

Authors:  Brad Spellberg; John Edwards; Ashraf Ibrahim
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

8.  Pulmonary aspergillosis: imaging findings with pathologic correlation.

Authors:  S L Aquino; S T Kee; M L Warnock; G Gamsu
Journal:  AJR Am J Roentgenol       Date:  1994-10       Impact factor: 3.959

Review 9.  Zygomycosis.

Authors:  M G Rinaldi
Journal:  Infect Dis Clin North Am       Date:  1989-03       Impact factor: 5.982

10.  Pulmonary zygomycosis: CT appearance.

Authors:  D A Jamadar; E A Kazerooni; B D Daly; C S White; B H Gross
Journal:  J Comput Assist Tomogr       Date:  1995 Sep-Oct       Impact factor: 1.826

View more
  7 in total

1.  Pulmonary mucormycosis: serial morphologic changes on computed tomography correlate with clinical and pathologic findings.

Authors:  Bo Da Nam; Tae Jung Kim; Kyung Soo Lee; Tae Sung Kim; Joungho Han; Myung Jin Chung
Journal:  Eur Radiol       Date:  2017-08-10       Impact factor: 5.315

2.  Three-dimensional-printed model of surgically resectable angioinvasive pulmonary mucormycosis.

Authors:  Catherine T Byrd; Devarsh Vyas; H Henry Guo; Natalie S Lui
Journal:  JTCVS Tech       Date:  2022-04-18

3.  How Long Do We Need to Treat an Invasive Mold Disease in Hematology Patients? Factors Influencing Duration of Therapy and Future Questions.

Authors:  Ana Fernández-Cruz; Russell E Lewis; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2020-07-27       Impact factor: 9.079

4.  Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome.

Authors:  Jun Feng; Xuefeng Sun
Journal:  Infection       Date:  2018-05-10       Impact factor: 3.553

Review 5.  Spectrum of imaging findings in pulmonary infections. Part 2: Fungal, mycobacterial, and parasitic.

Authors:  Mandeep Garg; Nidhi Prabhakar; Ajay Gulati; Ritesh Agarwal; Sahajal Dhooria
Journal:  Pol J Radiol       Date:  2019-04-22

Review 6.  Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic.

Authors:  Ayushi Sharma; Anjana Goel
Journal:  Folia Microbiol (Praha)       Date:  2022-02-26       Impact factor: 2.629

7.  The Integral Role of Radiology in the Diagnosis and Management of COVID-19-Associated Mucormycosis Infections.

Authors:  Anuj Prabhakar; Nidhi Prabhakar; Mandeep Garg; Ajay Kumar
Journal:  Am J Trop Med Hyg       Date:  2022-02-09       Impact factor: 2.345

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.